MRF-Logo2019-Horizontal-RGB
Lokking for patients that are in this clinical trial NCT01604889
REGISTER
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

Lokking for patients that are in this clinical trial NCT01604889

› Forums › General Melanoma Community › Lokking for patients that are in this clinical trial NCT01604889

  • Post
    • February 23, 2014 at 7:40 pm
    jim Breitfeller
    Participant

      A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma

      The study design includes an open-label, dose escalation phase followed by a blinded, randomized phase, which combines INCB024360 (an oral IDO inhibitor) with an approved therapy and compares to approved therapy plus placebo in metastatic melanoma patients.

      This IDO inhibitor regulates reprograming of the Tregs into TH-17 like Helper T-cells in tumor draining lymph nodes allowing the "Danger Signal"  to involke an immune response.

       

      In human melanoma, the presence of IDO-expressing cells in tumor-draining lymph nodes correlates with decreased long-term survival.

       

      This combination may increase the response rate and survival rate of Ipi (Yervoy).

      I am very interested in anyone that is on this Trial. Please chime in.

       

      Jimmy B

       

       

    Viewing 2 reply threads
    • Replies
        • February 23, 2014 at 7:52 pm
        jim Breitfeller
        Participant

          In your opinion, what is the most interesting recent clinical finding relating to IDO inhibitors?

          So far, it appears that indoximod is very favorable as a single agent and in combination with dendritic cell vaccines or docetaxel. This makes indoximod an ideal candidate to experiment with novel combinations using IDO inhibitors to augment the immune response from other checkpoint inhibitors such as CTLA-4 and PD-1/PD-L1 antibodies. There are preclinical data to support this idea, and some clinical experience to support this as well. One melanoma patient who previously received ipilimumab on a clinical trial was subsequently treated with indoximod. This patient developed de novo autoimmunity in the form of autoimmune hypophysitis and experienced prolonged disease stabilization. This gives us hope that the response rates to the checkpoint inhibitors can be enhanced by incorporation of IDO inhibitors into cancer immunotherapy protocols.

           

           

          Jimmy B

          • February 23, 2014 at 7:52 pm
          jim Breitfeller
          Participant

            In your opinion, what is the most interesting recent clinical finding relating to IDO inhibitors?

            So far, it appears that indoximod is very favorable as a single agent and in combination with dendritic cell vaccines or docetaxel. This makes indoximod an ideal candidate to experiment with novel combinations using IDO inhibitors to augment the immune response from other checkpoint inhibitors such as CTLA-4 and PD-1/PD-L1 antibodies. There are preclinical data to support this idea, and some clinical experience to support this as well. One melanoma patient who previously received ipilimumab on a clinical trial was subsequently treated with indoximod. This patient developed de novo autoimmunity in the form of autoimmune hypophysitis and experienced prolonged disease stabilization. This gives us hope that the response rates to the checkpoint inhibitors can be enhanced by incorporation of IDO inhibitors into cancer immunotherapy protocols.

             

             

            Jimmy B

            • February 23, 2014 at 7:52 pm
            jim Breitfeller
            Participant

              In your opinion, what is the most interesting recent clinical finding relating to IDO inhibitors?

              So far, it appears that indoximod is very favorable as a single agent and in combination with dendritic cell vaccines or docetaxel. This makes indoximod an ideal candidate to experiment with novel combinations using IDO inhibitors to augment the immune response from other checkpoint inhibitors such as CTLA-4 and PD-1/PD-L1 antibodies. There are preclinical data to support this idea, and some clinical experience to support this as well. One melanoma patient who previously received ipilimumab on a clinical trial was subsequently treated with indoximod. This patient developed de novo autoimmunity in the form of autoimmune hypophysitis and experienced prolonged disease stabilization. This gives us hope that the response rates to the checkpoint inhibitors can be enhanced by incorporation of IDO inhibitors into cancer immunotherapy protocols.

               

               

              Jimmy B

          Viewing 2 reply threads
          • You must be logged in to reply to this topic.
          About the MRF Patient Forum

          The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

          The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

          Popular Topics